SHORTCOMINGS IN THE TREATMENT OF LIVER DISEASES
Jild 4 son 34 (2025): Innovative research in the modern world: theory and practice 75-77
Annotatsiya
Liver diseases remain a serious medical and social problem because they often progress silently and are diagnosed only after significant structural and functional damage has developed. According to the World Health Organization, viral hepatitis continues to cause a major global disease burden and a high number of deaths each year, which shows that existing treatment opportunities do not always lead to timely and effective clinical outcomes [1], [2]. At the same time, the therapeutic challenge is not limited to viral hepatitis alone. Autoimmune, cholestatic, and metabolic liver diseases also require long-term management, but treatment results are frequently constrained by delayed diagnosis, insufficient etiological clarification, relapse, drug toxicity, and unequal access to advanced care [1], [3], [8].
Kalit soʻzlar:
Iqtiboslar
World Health Organization. Global Hepatitis Programme: Overview [Electronic resource]. – Access mode: WHO official website. – URL: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/overview (accessed: 23.04.2026).
World Health Organization. Viral hepatitis B and C burden of disease, WHO policy adoption status in countries, 2025: information sheet [Electronic resource]. – Geneva: WHO, 2025. – URL:
https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/2025-whd-hep-information-sheet.pdf (accessed: 23.04.2026).
National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Autoimmune Hepatitis [Electronic resource]. – Bethesda, MD: NIDDK. – URL:https://www.niddk.nih.gov/health-information/liver-disease/autoimmune-hepatitis/treatment (accessed: 23.04.2026).
Than J. Back to Basics: ANA-lyzing Autoimmune Hepatitis [Electronic resource]. – American Association for the Study of Liver Diseases, 15.04.2024. – URL: https://www.aasld.org/liver-fellow-network/core-series/back-basics/back-basics-ana-lyzing-autoimmune-hepatitis (accessed: 23.04.2026).
Dalekos G., Hartl J., Lenzi M., et al. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis [Electronic resource]. – Journal of Hepatology. – 2025. – URL: https://www.journal-of-hepatology.eu/article/S0168-8278(25)00173-4/fulltext (accessed: 23.04.2026).
U.S. Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease [Electronic resource]. – 14.03.2024. – URL: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (accessed: 23.04.2026).
Bowlus C.L., Lim J.K., Lindor K.D., et al. AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma [Electronic resource]. – Hepatology. – 2022. – URL: https://www.aasld.org/sites/default/files/2023-01/Hepatology%20-%202022%20-%20Bowlus%20-%20AASLD%20practice%20guidance%20on%20primary%20sclerosing%20cholangitis%20and%20cholangiocarcinoma.pdf (accessed: 23.04.2026).
World Health Organization. Transplantation [Electronic resource]. – Access mode: WHO official website. – URL: https://www.who.int/health-topics/transplantation (accessed: 23.04.2026).
World Health Organization. Human organ and tissue transplantation [Electronic resource]. – Geneva: World Health Organization, 2022. – URL: https://apps.who.int/gb/ebwha/pdf_files/WHA75/A75_41-en.pdf (accessed: 23.04.2026).
Oʻquvchilar geografiyasi
Yuklab olishlar
Nashr qilingan
Son
Boʻlim
Iqtibos keltirish tartibi
